Navigation Links
Phase Genomics Announces Availability of Kit-based ProxiMeta™ Hi-C Metagenome Deconvolution

Phase Genomics, the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can use the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta offering launched in May 2017. Additionally, a newly available paper demonstrates the technology’s power to assemble over 250 genomes from a single human fecal sample.

“Using the ProxiMeta kit and our computational tools, researchers can now assemble numerous high-quality genomes from mixed samples without culturing, high-molecular-weight DNA extraction, or any a priori information,” said Dr. Ivan Liachko, CEO of Phase Genomics. “The applications of this technology are broad and exciting, and we’ve shown that ProxiMeta can be used to discover many novel species, detect plasmid-host interactions, and identify strain-level genetic variation. We are even more excited to see all the discoveries that this technology will enable as it is adopted by the wider scientific community.”

Microbiome samples are made up of many different microorganisms that must be sequenced together. A key challenge in metagenomics is determining which DNA sequences originated from which organism in the mix. ProxiMeta solves this problem using an enhanced version of the chromatin capture technique Hi-C, which measures the physical structure of microbial genomes while their cells are still intact.

This powerful innovation enables researchers to study individual microbial communities with unprecedented precision, opening the door to deeper, more rapid discoveries in fields like the microbiome, infectious disease, agriculture, and antibiotic resistance.

"Phase Genomics' ProxiMeta Hi-C solution makes innovative use of Illumina reads to conduct metagenomic deconvolution and extract more complete sequence information from mixed microbiome samples,” said Gary Schroth, PhD, Vice President of Genomics Development and Distinguished Scientist for Illumina. “This technology promises to open many new metagenomic applications and we’re excited to see it come to market."

ProxiMeta™ includes a kit for sample processing, cloud-based software for analysis, and full customer support. For more information, email your inquiry to info(at)phasegenomics(dot)com or visit their website at

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Multidisciplinary Association for Psychedelic Studies (MAPS) Selects Montriums eTMF Platform as They Begin Phase 3 Studies of MDMA-assisted Psychotherapy for PTSD
2. GeneOne Life Science Receives Approval for Phase I/IIa MERS-CoV Vaccine Trial in Korea
3. SFC Fluidics, Inc. Receives SBIR Phase II Funding for Development of an Implantable Drug Delivery Device
4. Allotrope Foundation Achieves Two Major Milestones: Releases 1st Phase of Framework for Commercial Use and is Recognized with a 2017 Bio-IT World Best Practice Award
5. Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
6. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
7. Three Phase 1 Ventures Participants Receive Science Center Funding
8. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
9. JDP Initiates Pivotal Phase 3 Clinical Trial of JDP-205 for Acute Urticaria
10. Phase Genomics Announces the Commercial Availability of ProxiMeta™ Hi-C
11. Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Post Your Comments:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):